An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST: T1)
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart; Insulin detemir
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms BOOST-T1
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 16 Jan 2016 Primary endpoint has been met (Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes), according to results published.
- 16 Jan 2016 Results published in the Diabetic Medicine.